An observational study in Heart Failure and Heart Decompensation, sponsored by Corteria Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-13.
Sponsored by Corteria Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This observational study is conducted to assess the evolution of multiple markers of congestion over 4 weeks after a worsening heart failure (WHF) event treated in an outpatient unit
This is a multicenter, non-randomized, observational study designed to assess the evolution of multiple markers (physical, echocardiographic, and biomarkers) of congestion in 40 patients with chronic heart failure (CHF) treated over 4 weeks with 40 to 120 mg daily oral furosemide after an event of WHF treated in an outpatient unit. Patients at selected centers may participate in a telemetry ancillary study, in which real-time, continuous, non-invasive measurements of physiologic parameters of heart failure will be obtained through use of a wearable medical telemetry device.
Approximately 40 patients with CHF with reduced or mildly reduced left ventricular ejection fraction (EF \< 50%) who had an admission for WHF in the preceding 1-12 months and who develop symptoms of WHF over the week before presentation to an outpatient clinic will be enrolled. Patients will attend five outpatient visits over the course of 4 weeks.
At each visit, the patient's vital signs will be measured, clinical assessments (NYHA class, jugular vein distension, peripheral edema score, pulmonary rales) will be performed, and blood samples for central assays will be obtained. Detailed echocardiographic examination will be performed prior to enrolment in the first visit and at Visit 5.
Biomarkers related to cardiac and renal function will be measured in blood and urine samples at each visit.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
This study's enrollment of 42 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Corteria Pharmaceuticals is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Approximately 40 adult male and female patients with a diagnosis of HFrEF (EF\<40%) and HFmrEF (EF >40 \< 50%) who had a hospital admission for HF within 1 to12 months prior to screening and developed worsening symptoms of HF during the week prior to presentation to an outpatient clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ambulatory patients with a diagnosis of stable class II - III HF with \<50%, who experience a worsening of heart failure (WHF), with worsening signs and/or symptoms of heart failure requiring institution or up titration of loop diuretic therapy, in the week preceding their visit to the outpatient HF clinic and with at the time of Screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
Change in E/e' ratio
Change in E/e' ratio, measured on echocardiography
Time frame: Screening (Visit 1) and week 4 (beginning of Visit 5).
Changes in Left Ventricular End-Diastolic Diameter (LVEDD)
Changes in LVEDD measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Left Ventricular End-Systolic Diameter (LVESD)
Changes in LVESD measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Left Ventricular End-Diastolic Volume (LVEDV)
Changes in LVEDV measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Left Ventricular End-Systolic Volume (LVESV)
Changes in LVESV measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Left Ventricular Ejection Fraction (LVEF)
Changes in LVEF measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in mitral E-velocity
Changes in mitral E-velocity measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in mitral A-velocity
Changes in mitral A-velocity measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in E' velocity
Changes in E' velocity measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Right Ventricular Systolic Pressure (RVSP)
Changes in RVSP measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Tricuspid Annular Pulmonary Systolic Excursion (TAPSE)
Changes in TAPSE measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in S' velocity
Changes in S' velocity measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Inferior Vena Cava (IVC) diameter
Changes in IVC (minimum and maximum) measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Left Atrium (LA) surface
Changes in LA surface measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in Right Atrium (RA) surface
Changes in RA surface measured on echocardiography from screening to Week 4
Time frame: From screening to 4 weeks
Changes in patient-reported dyspnea
Weekly changes in patient-reported dyspnea
Time frame: From screening to 4 weeks
Changes in clinically-assessed jugular venous pulse
Weekly changes in clinically-assessed jugular venous pulse
Time frame: From screening to 4 weeks
Changes in clinically-assessed peripheral edema
Weekly changes in peripheral edema
Time frame: From screening to 4 weeks
Changes in estimated Glomerular Filtration Rate (eGFR)
Changes in eGFR between screening, Week 2 and Week 4 visit.
Time frame: From screening to 4 weeks
Changes in serum creatinine
Changes in serum creatinine between screening, Week 2 and Week 4 visit.
Time frame: From screening to 4 weeks
Changes in NT-proBNP
Changes in NTproBNP between screening, Week 2 and Week 4 visit.
Time frame: From screening to 4 weeks
Changes in high sensitivity Troponin T (HsTnT)
Changes in HsTnT between screening, Week 2 and Week 4 visit.
Time frame: From screening to 4 weeks
Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ)-12
Changes in KCCQ-12 inclusive of total symptoms score and sub scores from screening to Week 4
Time frame: From screening to 4 weeks
Weekly changes in telemetered parameters in patients wearing the wrist-worn device (Philips Health Band)
Weekly changes in activity in those patients wearing the wrist-worn device (Philips Health Band)
Time frame: From screening to 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Apr 2023, 6 months.
Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's 6 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Corteria Pharmaceuticals